Clinical Trials Logo

Advanced Kidney Cancer clinical trials

View clinical trials related to Advanced Kidney Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03308396 Active, not recruiting - Kidney Cancer Clinical Trials

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Start date: December 19, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, multi-centre (via Big Ten Cancer Research Consortium) phase Ib/II study of patients treated with durvalumab 1500 mg IV q 4 weeks in combination with guadecitabine at the recommended phase 2 dose subcutaneously for 5 consecutive days. Eligible patients will have metastatic RCC with a clear cell component, ECOG performance status of 0-1, have received 0-1 prior therapy but no prior anti-PD-1/PD-L1/CTLA4 (Cohort 1, 36 subjects). Study treatment could potentially continue for up to 13 cycles (52 weeks).